Author of the publication

High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.

, , , , , and . Lancet, (Dec 15, 2001)Recently, the Apolipoprotein-Related Mortality Risk Study published prospective data in 175,553 men and women and found that the total apo B level was a better predictor of future CAD risk than LDL cholesterol.<br /><br />Importantly, they also found that apo B was a better predictor of CAD risk in individuals with low LDL levels, supporting the idea that patients with low LDL cholesterol levels and increased quantities of small, dense atherogenic particles (VLDL, IDL, and LDL) are at risk for CAD. (scavalieri 2005-08-21 21:51:58).

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel., , , , , , , , , and 20 other author(s). J Intern Med, 259 (3): 247--258 (March 2006)High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study., , , , , and . Lancet, (Dec 15, 2001)Recently, the Apolipoprotein-Related Mortality Risk Study published prospective data in 175,553 men and women and found that the total apo B level was a better predictor of future CAD risk than LDL cholesterol.<br /><br />Importantly, they also found that apo B was a better predictor of CAD risk in individuals with low LDL levels, supporting the idea that patients with low LDL cholesterol levels and increased quantities of small, dense atherogenic particles (VLDL, IDL, and LDL) are at risk for CAD. (scavalieri 2005-08-21 21:51:58).Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment., , , , , , and . Lancet, 361 (9359): 777--780 (March 2003)